Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday

Key Points

• Vanda Pharmaceuticals is set to release its Q3 2025 earnings on October 29th, with expectations of reporting earnings of ($0.38) per share and revenue of $58.73 million.
• In its previous quarter, Vanda reported a loss of ($0.46) EPS, missing the consensus estimate and showing a negative return on equity of 12.89%.
• Analysts have mixed ratings for Vanda Pharmaceuticals, with a consensus rating of "Moderate Buy" and a target price of $16.50, but several firms have issued sell ratings.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.38) per share and revenue of $58.7330 million for the quarter. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.Interested persons may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The company had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. On average, analysts expect Vanda Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA stock traded up $0.15 during trading on Thursday, hitting $5.49. 687,759 shares of the company were exchanged, compared to its average volume of 547,894. The firm has a market capitalization of $324.40 million, a price-to-earnings ratio of -4.86 and a beta of 0.74. The business's 50-day simple moving average is $4.85 and its 200 day simple moving average is $4.59. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $5.59.

Wall Street Analyst Weigh In

Several research firms recently commented on VNDA. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. Wall Street Zen cut shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 2nd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several large investors have recently bought and sold shares of VNDA. Royal Bank of Canada raised its stake in Vanda Pharmaceuticals by 34.3% during the 1st quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company's stock valued at $256,000 after purchasing an additional 14,232 shares during the last quarter. Millennium Management LLC raised its stake in Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company's stock valued at $9,821,000 after purchasing an additional 1,470,898 shares during the last quarter. Hsbc Holdings PLC raised its stake in Vanda Pharmaceuticals by 17.6% during the 2nd quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company's stock valued at $319,000 after purchasing an additional 9,960 shares during the last quarter. Norges Bank bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at $543,000. Finally, Walleye Capital LLC increased its holdings in Vanda Pharmaceuticals by 155.1% in the 2nd quarter. Walleye Capital LLC now owns 94,298 shares of the biopharmaceutical company's stock valued at $445,000 after buying an additional 57,332 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.